Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 19Completed 14Active not recruiting 10Unknown 6Terminated 5Withdrawn 3Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 39Stomach Neoplasms 20Carcinoma, Hepatocellular 20Pancreatic Neoplasms 15Colonic Neoplasms 13Esophageal Neoplasms 10Liver Neoplasms 9Rectal Neoplasms 8Esophageal Squamous Cell Carcinoma 8Cholangiocarcinoma 8Breast Neoplasms 8Barrett Esophagus 8Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Postoperative Complications 4Liver Cirrhosis 4Gastrointestinal Neoplasms 4Gallbladder Neoplasms 4Diabetes Mellitus 4Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Lymphatic Metastasis 3Lung Neoplasms 3Fibrosis 3Colorectal Neoplasms, Hereditary Nonpolyposis 3Anastomotic Leak 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2

Interventions

irinotecan sucrosofate 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Gastro-enteropancreatic neuroendocrine tumor × Gastrointestinal × Clear all
NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡